Author: Ashish Goyal; E. Fabian Cardozo-Ojeda; Joshua T Schiffer
Title: Potency and timing of antiviral therapy as determinants of duration of SARS CoV-2 shedding and intensity of inflammatory response Document date: 2020_4_14
ID: d7stppv5_24
Snippet: Early initiation of a highly potent therapy was predictive of lower shedding duration whether given in the pre-peak asymptomatic phase or in the post-peak symptomatic phase beyond day 2-4 of infection. However, extremely early initiation of a lower potency therapy was predicted to prolong shedding relative to no treatment (Fig. 5a) ......
Document: Early initiation of a highly potent therapy was predictive of lower shedding duration whether given in the pre-peak asymptomatic phase or in the post-peak symptomatic phase beyond day 2-4 of infection. However, extremely early initiation of a lower potency therapy was predicted to prolong shedding relative to no treatment (Fig. 5a) .
Search related documents:
Co phrase search for related documents- early initiation and extremely early initiation: 1, 2, 3, 4
- early initiation and highly potent therapy: 1
- early initiation and potency therapy: 1
- early initiation and symptomatic phase: 1
- extremely early initiation and highly potent therapy: 1
- extremely early initiation and symptomatic phase: 1
- highly potent therapy and symptomatic phase: 1
- low potency therapy and potency therapy: 1
Co phrase search for related documents, hyperlinks ordered by date